BW
SLXNW

Boaz Weinstein’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Boaz Weinstein’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,937
Closed -$242 – 440
2026
Q1 		$242 Hold
11,937
– – ﹤0.01% 389
2025
Q4 		$318 Hold
11,937
– – ﹤0.01% 350
2025
Q3 		$421 Hold
11,937
– – ﹤0.01% 329
2025
Q2 		$488 Hold
11,937
– – ﹤0.01% 322
2025
Q1 		$835 Hold
11,937
– – ﹤0.01% 266
2024
Q4 		$488 Hold
11,937
– – ﹤0.01% 285
2024
Q3 		$606 Buy
+11,937
New +$691 ﹤0.01% 355

Other funds holding SLXNW

OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Boaz Weinstein's SLXNW Position: Q2 2026 in Review

Boaz Weinstein sold out of Silexion Therapeutics Warrant (SLXNW) in Q2 2026, closing a stake of 11,937 shares — an estimated $242 sold.

Boaz Weinstein first reported a position in SLXNW in Q3 2024 and held it in 7 quarters. The position peaked at $835 in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q2 2026.

  • Boaz Weinstein reported no remaining Silexion Therapeutics Warrant position as of Q2 2026 after selling out during the quarter.
  • Boaz Weinstein sold 11,937 Silexion Therapeutics Warrant shares in Q2 2026, an estimated $242.
  • Boaz Weinstein first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 7 quarters.
  • Boaz Weinstein's Silexion Therapeutics Warrant position peaked at $835 in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2026.

Based on Saba Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.